Flores, A. J., Bartlett, M. J., Root, B. K., Parent, K. L., Heien, M. L., Porreca, F., . . . Falk, T. (2018). The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced L-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. Neuropharmacology.

Flores, Andrew J., Mitchell J. Bartlett, Brandon K. Root, Kate L. Parent, Michael L. Heien, Frank Porreca, Robin Polt, Scott J. Sherman, and Torsten Falk. "The Combination of the Opioid Glycopeptide MMP-2200 and a NMDA Receptor Antagonist Reduced L-DOPA-induced Dyskinesia and MMP-2200 By Itself Reduced Dopamine Receptor 2-like Agonist-induced Dyskinesia." Neuropharmacology 2018.

Flores, Andrew J., et al. "The Combination of the Opioid Glycopeptide MMP-2200 and a NMDA Receptor Antagonist Reduced L-DOPA-induced Dyskinesia and MMP-2200 By Itself Reduced Dopamine Receptor 2-like Agonist-induced Dyskinesia." Neuropharmacology 2018.